Credit: Sense Neuro Diagnostics Sense Diagnostics announces initiation of clinical trial to evaluate a non-invasive brain scanner to monitor intracranial hemorrhage SENSE device uses low-power tailored radio frequency (RF) pulse to detect changes that may indicate expanding brain bleed Current standard of care lacks a means to monitor brain injury continuously, non-invasively, in real time, between CT scans CINCINNATI, OH - March 16, 2021 - Sense Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, announced the initiation of a multicenter pivotal trial to evaluate the safety and efficacy of a non-invasive brain scanner to monitor intracranial hemorrhage (ICH) in an acute hospital setting. The SENSE device is a headset equipped with antennae that transmit a low-power tailored radio frequency (RF) pulse across the brain and uses an algorithm to detect signal changes that may indicate an expansion in ICH.